Altria Group Inc FY2024 Financial Report: Revenue $24.0B Decreased 1.8% YoY, Net Income $11.3B Up 38.7%

Executive Summary

Altria Group Inc reported total revenues of $24.0 billion for FY2024, reflecting a slight decrease of 1.8% compared to FY2023, primarily driven by lower cigarette sales and regulatory impacts. Net earnings surged to $11.3 billion, a 38.7% increase YoY, mainly due to gains from asset sales and favorable tax adjustments. The company maintains a strong balance sheet with total assets of $35.2 billion and a debt level of $24.9 billion, resulting in a debt-to-equity ratio of approximately 11.4. Cash flows from operating activities remained robust at $8.75 billion, supporting ongoing share repurchases and dividend payments. The key performance metrics indicate a resilient business model with improving profitability margins despite modest revenue declines.

Key Metrics

Management Discussion and Analysis

Despite a challenging regulatory environment and declining cigarette volumes, Altria has demonstrated strong earnings growth driven by asset sales, strategic investments, and tax benefits. Revenue decline was primarily due to reduced cigarette sales volume, impacted by market shifts and regulatory restrictions. The company’s focus on premium products and reduced-risk alternatives has helped sustain margins. Cash flow generation remains healthy, enabling continued share repurchases and dividend increases. The company is actively managing its debt levels and optimizing its asset portfolio to enhance shareholder value and mitigate long-term risks.

Income Statement Analysis

Revenue decreased by 1.8% YoY from $24.5 billion to $24.0 billion, mainly due to lower cigarette sales. Gross profit increased marginally by 0.6%, reflecting improved product mix and cost efficiencies. Operating income declined by 2.7%, impacted by higher marketing and regulatory compliance costs. Net income surged by 38.7%, primarily due to gains from asset sales and favorable tax adjustments, reaching $11.3 billion. Earnings per share (diluted) remained stable at $6.54, supported by share repurchases and a lower share count.

Balance Sheet Analysis

Assets totaled $35.2 billion, down 8.8% from $38.6 billion, mainly due to asset disposals and impairments. Cash and cash equivalents stood at $3.1 billion, a decrease from $3.7 billion. Receivables increased slightly to $177 million. Inventories declined to $1.08 billion, reflecting inventory management strategies. Total liabilities decreased to $37.4 billion, with long-term debt at $23.4 billion, down 4.9%. Shareholders’ equity improved to a deficit of $2.2 billion from $3.5 billion, driven by net earnings and asset sales, indicating a strengthening of the company’s financial position.

Cash Flow Analysis

Operating cash flow was $8.75 billion, a decrease of 5.7% YoY, mainly due to timing of receivables and regulatory payments. Investing activities generated $2.2 billion, primarily from asset sales, including the IQOS rights and investments in equity securities. Capital expenditures were modest at $142 million, focused on product innovation and manufacturing upgrades. Financing activities involved debt repayment of $1.1 billion, share repurchases of $3.4 billion, and dividend payments totaling $6.8 billion. The company maintains a strong liquidity position to support strategic initiatives and shareholder returns.

Ratios & DuPont Analysis

Net profit margin improved significantly to 47.0% from 33.2% YoY, driven by asset sale gains and tax benefits. Return on assets (ROA) increased to 32.2% from 21.0%, reflecting higher net income relative to total assets. Return on equity (ROE) was positive at 514%, a substantial improvement from negative levels, indicating effective leverage and profitability. Asset turnover remained stable at 0.68, showing consistent utilization of assets. The equity multiplier increased to 11.4, highlighting leverage’s role in enhancing ROE.

Risk Factors

Altria faces regulatory risks from evolving tobacco laws, including potential restrictions on nicotine products and advertising. Market risks include declining cigarette volumes and competition from reduced-risk alternatives. Operational risks involve supply chain disruptions and compliance costs. Financial risks relate to debt levels and interest rate fluctuations. Macro risks include inflation, economic downturns, and changing consumer preferences. The company’s strategic investments and portfolio management aim to mitigate these risks and sustain long-term growth.

Notes & Additional Commentary

Unusual items include a $2.7 billion gain from IQOS rights sale and asset sale proceeds. The company’s impairment charges relate to the Skoal trademark and other intangible assets, reflecting market volume declines and valuation adjustments. The company’s debt management and share repurchase programs support shareholder value. Regulatory developments, especially related to JUUL and e-vapor litigation, remain key uncertainties. The company’s focus on innovation and cost control positions it well for future challenges and opportunities.

Investment Implications

Altria’s strong cash flow and strategic asset sales provide a solid foundation for shareholder returns through dividends and buybacks. The company’s diversified portfolio and focus on reduced-risk products offer growth opportunities, though regulatory and market headwinds persist. Long-term investors should monitor regulatory developments and market share trends in traditional and alternative tobacco products. The company’s leverage and asset impairment risks warrant cautious optimism, balanced by its resilient earnings and cash generation capabilities.